1-(T-Butoxycarbonyl)Pyrrole-2-Boronic Acid

Atorvastatin calcium manufacture relies on a convergent assembly where a fully elaborated chiral 3-hydroxy-δ-lactone side chain is attached to a 1H-pyrrole core carrying a 2-(4-fluorophenyl) substituent. The regioselective installation of this 2-aryl group is achieved via a Suzuki-Miyaura cross-coupling between 1-(tert-butoxycarbonyl)pyrrole-2-boronic acid and 4-fluorobromobenzene. Commercial-scale batches in 500 L glass-lined reactors under nitrogen atmosphere with anchor-type agitation consistently document that the acceptor aryl halide should be charged in a 1.08–1.15 molar ratio relative to the limiting boronic acid partner to compensate for the parasitic protodeboronation rate (0.2–0.4 % h⁻¹) measured at 80 °C in THF:water (3:1 v/v) using Pd(PPh₃)₄ at 0.3 mol % loading and K₂CO₃ at 2.5 equivalents. Exceeding 1.30 equivalents promotes detectable homocoupling of the fluorobromobenzene and accelerates formation of the 2-aryl pyrrole dimers that co-crystallise with the desired intermediate, reducing isolated purity below 98.0 area% by HPLC. After phase separation, the organic layer is washed with 5 % (w/w) HCl to scavenge residual palladium, concentrated, and treated with trifluoroacetic acid in dichloromethane (20 % v/v, 25 °C, 3 h) to cleave the tert-butoxycarbonyl group; the resulting 2-(4-fluorophenyl)-1H-pyrrole is isolated as a crystalline solid that is telescoped directly into the subsequent Vilsmeier formylation step without intermediate drying. This specific intermediate falls under ICH Q7 active pharmaceutical ingredient GMP guidance and 21 CFR 210/211 when destined for drug substance manufacturing. The terminal product is atorvastatin calcium, a genericised HMG-CoA reductase inhibitor formulated as oral tablets compliant with current USP and Ph.Eur. monographs.

Why Does Pd(OAc)₂/PPh₃ Outperform Pd(dppf)Cl₂ in Sterically Hindered 2-Aryl Pyrrole Synthesis?

Kinase inhibitor programs targeting oncogenic mutations such as FLT3-ITD or BTK C481S frequently demand 2-aryl pyrrole fragments bearing bulky ortho substituents on the aromatic ring that are incompatible with rigid bisphosphine–palladium catalysts. Under microwave-assisted conditions in a Biotage® Initiator+ single-mode reactor, the coupling of 1-(tert-butoxycarbonyl)pyrrole-2-boronic acid with 2,6-dimethylbromobenzene proceeds with a 91 % isolated yield when Pd(OAc)₂ (1.0 mol%) and PPh₃ (2.2 mol%) are employed at 110 °C in DMF:water (4:1) with NaHCO₃ (3.0 eq), whereas an equivalent run using Pd(dppf)Cl₂ (1.5 mol%) returns only 54 % conversion and a homocoupling by-product exceeding 12 area%. The boronic acid addition ratio is tightly clamped to 1.00–1.05 equivalents relative to the sterically congested aryl bromide because any excess remains as a poorly soluble residual boroxine after the aqueous workup, complicating downstream flash chromatographic purification on silica gel 60 (230–400 mesh). The downstream synthesis proceeds through a Boc-deprotection cascade using anhydrous HCl in 1,4-dioxane (4 M, 20 °C) followed by nucleophilic substitution on the liberated N–H pyrrole to install a chloroacetamide linker before coupling to a warhead-bearing quinazoline. Compliance with ICH Q3D requires residual palladium in the final late-stage intermediate to be maintained below 10 µg g⁻¹; this is achieved by charcoal cartridge filtration (Norit® SX Plus) after the Suzuki step. The terminal product class comprises orally bioavailable irreversible BTK inhibitors and related covalent fragments currently in Phase I/II clinical evaluation.

Host-to-Dopant Energy Transfer Efficiency in Phosphorescent Emitters with Pyrrole Donors

Solution-processed phosphorescent organic light-emitting diode (PHOLED) host materials engineered with alternating 2-aryl pyrrole donor blocks and triazine acceptor blocks rely on a precise 1:1 stoichiometric balance during the Suzuki polycondensation to achieve a number-average molecular weight (M_n) exceeding 35 000 g mol⁻¹ and a dispersity below 2.0. The bifunctional monomer 1-(tert-butoxycarbonyl)pyrrole-2-boronic acid is reacted with 1,3-dibromo-5-(tert-butyl)benzene at a rigorous molar equivalence of 1.000 ± 0.002 in anhydrous chlorobenzene using Pd₂(dba)₃ (0.8 mol%) and P(o-tol)₃ (3.2 mol%). The reaction is maintained at 120 °C for 24 h in a 10 L jacketed vessel equipped with a pitched-blade turbine; an inline Raman spectroscopy probe tracks the C–Br vibrational band disappearance to determine the endpoint to avoid chain scission from overheating. The crude Boc-protected polymer is precipitated twice from methanol (10 volumes) and then treated with trifluoroacetic acid (TFA) in dry CH₂Cl₂ (1:1 v/v) at 25 °C for 12 h under argon to release the free N–H pyrrole units that raise the HOMO level to −5.2 eV and function as hole-transporting sites. Purification by preparative size-exclusion chromatography (Bio-Beads™ S-X1, THF eluent) followed by fractional precipitation removes low-molecular-weight oligomers and residual palladium to below 5 µg g⁻¹ as measured by ICP-MS (Agilent 7900). The final sublimed-grade host material passes the electronic-grade metals specification of < 1 ppm total non-volatile residue and displays a photoluminescence quantum yield (PLQY) of 0.87 ± 0.03 when doped with 8 wt% fac-tris(2-phenylpyridine)iridium(III). The terminal products are solution-cast phosphorescent green OLED devices with current efficiencies reported above 60 cd A⁻¹ at 1000 cd m⁻² luminance, intended for consumer AMOLED display panels compliant with IEC 62321-1 restricted substances protocols.

Fluxapyroxad and related pyrazole-3-carboxamides represent a well-succeeded succinate dehydrogenase inhibitor (SDHI) class, yet the search for alternative heterocyclic cores with lower soil residual persistence (DT₅₀) has driven the preparation of 2-aryl pyrrole-3-carboxylic acid building blocks. 1-(tert-butoxycarbonyl)pyrrole-2-boronic acid is coupled with 4-chloro-3-(trifluoromethyl)bromobenzene under aqueous micellar conditions using 2 wt% aqueous TPGS-750-M as the reaction medium, Pd(OAc)₂ (1.5 mol%), XPhos (3.0 mol%), and K₃PO₄ (3.0 eq) at 60 °C for 8 h. The addition ratio of boronic acid to aryl bromide is set at 1.10 eq to offset the slightly accelerated protodeboronation observed in purely aqueous surfactant solutions. After coupling, the reaction mixture is acidified to pH 2 with 6 N HCl, which simultaneously cleaves the Boc group and hydrolyses the tert-butyl ester at the pyrrole 3-position that had been installed prior to the borylation step; this one-pot deprotection hydrolysis is quenched by extraction into ethyl acetate, and the resulting 2-(4-chloro-3-trifluoromethylphenyl)pyrrole-3-carboxylic acid is crystallised from heptane:ethyl acetate (4:1). The downstream process continues to the corresponding acid chloride and subsequent amidation with a substituted biaryl amine fragment. Compliance is demonstrated against OECD Test No. 301F (ready biodegradability) for aqueous waste streams and against FAO pesticide specifications for technical-grade active ingredient purity. Residual palladium control at < 20 µg g⁻¹ is mandatory per CIPAC MT 4102 collaborative study guidelines. The terminal formulations are granular SDHI fungicides targeting Septoria tritici blotch and Asian soybean rust.

When Gas Sorption Selectivity Depends on Free N–H Sites: Deblocking Boc-Protected Precursors Post-Polymerisation

Microporous conjugated polymers designed for post-combustion CO₂/N₂ separation exploit the hydrogen-bonding affinity of unprotected pyrrole N–H donors. A tetrahedral building block, tetrakis(4-bromophenyl)methane, is subjected to Suzuki cross-coupling with 1-(tert-butoxycarbonyl)pyrrole-2-boronic acid at a molar feed ratio of 1:2.2 (boronic acid to tetra-bromide) to ensure complete surface bromine consumption and to generate a hyperbranched architecture. The reaction is conducted in a 2 L Parr® high-pressure reactor at 90 °C using a dioxane:water (5:1) mixture, Pd(PPh₃)₄ (2 mol%), and K₂CO₃ (4 eq per Br) with vigorous mechanical stirring at 400 rpm for 48 h. The occluded Boc-groups are subsequently removed by heating the isolated polymer in 6 N HCl (aq) at reflux (110 °C) for 12 h, monitored by FT-IR attenuation of the carbonyl stretching band at 1705 cm⁻¹. After deprotection, the surface area measured by nitrogen physisorption at 77 K following the ISO 9277:2022 BET method increases from 420 m² g⁻¹ to 850 m² g⁻¹, and the CO₂ uptake at 298 K, 1 bar reaches 2.8 mmol g⁻¹ with a CO₂/N₂ selectivity of 45 computed by ideal adsorbed solution theory (IAST). The downstream production process does not seek pharmaceutical-grade certification; however, the residual palladium content is controlled below 50 µg g⁻¹ through a Soxhlet extraction with 1:1 acetone:thiourea solution to avoid catalytic degradation during long-term gas exposure. The terminal products are structured adsorbents incorporated into hollow-fibre membrane contactors or pressure-swing adsorption beds for landfill gas upgrading and flue-gas decarbonisation.

Addressing Homocoupling By-Product Formation through Steric Masking of the Boron Centre

Preparatory-scale synthesis of pyrrole-containing proteasome inhibitor fragments relies on the chemoselectivity imparted by the bulky tert-butoxycarbonyl substituent on the pyrrole nitrogen atom. In a documented large-scale campaign, 1-(tert-butoxycarbonyl)pyrrole-2-boronic acid was reacted with 2-chloro-5-iodothiazole using Pd/C (5 wt%, Type 487) as a recoverable heterogeneous catalyst in ethanol:water (4:1) at 78 °C under an atmosphere of 5:95 H₂:N₂ gas mixture to maintain palladium in the active zero-valent state. The boronic acid addition ratio was fixed at 1.20 equivalents relative to the heteroaryl chloride-iodide substrate to compensate for the slower oxidative addition of the chloride bond, while the free N–H pyrrole analogue under identical conditions generated >15 area% of symmetrical biaryl homocoupling impurity. The bis-Boc protected variant retained homocoupling below 2.0 area% as quantified by GC-FID (Agilent DB-5 30 m). After filtration through a 0.45 µm PTFE in-line cartridge to recover the catalyst, the Boc group is removed using methanesulfonic acid (1.2 eq) in isopropyl acetate at 20–25 °C, precipitating the deprotected 2-heteroaryl pyrrole as the mesylate salt; this avoids the aqueous washes that would otherwise cause product emulsification. The downstream sequence involves reductive amination with a morpholinyl-aldehyde side chain, followed by dipeptide conjugation to assemble the epoxyketone warhead. The process is operated under ICH Q7 Chapter 12 rules for early-stage intermediates, and elemental impurity risk assessment per ICH Q3D requires palladium levels in the crude mesylate salt to remain below 50 µg g⁻¹ prior to the final coupling. The terminal product is an injectable irreversible proteasome inhibitor homologue intended for refractory multiple myeloma treatment.